Client News
Roquefort Therapeutics PLC – Director/PDMR ShareholdingRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, advises that Ajan Reginald, Chief Executive Officer has purchased ordinary shares in the Company, as detailed below:
|
Number of Ordinary Shares |
Average Price Paid Per Share |
Total Consideration Paid |
|
35,265 |
7.06 pence |
£2,489.27 |
Following the above purchase of shares, Ajan Reginald holds an interest in 11,663,051 Company ordinary shares.
Director/PDMR Shareholding – 10:00:10 26 Jun 2023 – ROQ News article | London Stock Exchange
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
CLIENT AREA
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.